Tags |
|
|
Links |
|
|
Suggest - The Point Behind Point & Figure
After receiving the e-mail I sent out last week, a client called and asked “what is the point of all of these charts that you refer to?”
I told her that “point and figure charts, and the strateg
I told her that “point and figure charts, and the strateg
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
y that I use with those charts, is designed to prevent you from being involved in a disaster.”
I asked her to humor me for a moment and let me tell her about a gentleman I recently met.
In 1998
I asked her to humor me for a moment and let me tell her about a gentleman I recently met.
In 1998
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
, he decided that he’d retire in mid-2000, when he turned 65.
Back then, his 401k plan was worth $1,214,000.
He expected to withdraw $80,000 per year from the plan (or about 6 to 7% of the bala
Back then, his 401k plan was worth $1,214,000.
He expected to withdraw $80,000 per year from the plan (or about 6 to 7% of the bala
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ce), when he figured this out in 1998.
He went on to tell me that he expected this would be a reasonable amount, because the market had returned an average of 15% per year for the previous 15 ye
He went on to tell me that he expected this would be a reasonable amount, because the market had returned an average of 15% per year for the previous 15 ye
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ars.
Even if the market didn’t make 15%, he said, he read somewhere that “over the long haul, the market returned a little over 10% per year, going back to the 1920’s.”
So, since he planned to
Even if the market didn’t make 15%, he said, he read somewhere that “over the long haul, the market returned a little over 10% per year, going back to the 1920’s.”
So, since he planned to
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
nly take out 6 or 7% per year, and it’s growing at least by 10% or more, he estimated he would never run out of money.
So he made big plans!
He planned to renovate his house, put in a pool. Al
So he made big plans!
He planned to renovate his house, put in a pool. Al
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
so do a little traveling, something he never had time to do while he was raising a family and working. His wife also made plans to stop working as well.
His retirement date was Friday, April 14,
His retirement date was Friday, April 14,
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
2000; his 401K had a value of $1,277,000.00.
One year later, in April, 2001, his 401K plan had a value of $979,000.
By December 2002, his 401k account was worth $764,000.
He had not even made
One year later, in April, 2001, his 401K plan had a value of $979,000.
By December 2002, his 401k account was worth $764,000.
He had not even made
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
a withdrawal yet, but his solar-powered calculator told him bad news: he’d be scrounging for money by the time he was 76. The $80,000.00 per year he planned to take out would now drain this acco
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
nt entirely in about nine years.
The distribution was scaled back, from $80,000 to $24,000.00 a year.
Going from $80,000 to $24,000 a year was a lifestyle change for him. He felt burned. Dream
The distribution was scaled back, from $80,000 to $24,000.00 a year.
Going from $80,000 to $24,000 a year was a lifestyle change for him. He felt burned. Dream
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
s of traveling went out the window. Buy a new car? No chance.
His wife has taken a job in the library. He’s now back at work, as a consultant, hustling for jobs. And now he’s just learned tha
His wife has taken a job in the library. He’s now back at work, as a consultant, hustling for jobs. And now he’s just learned tha
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
t his former company is changing their healthcare plan for their retirees.
What if this were you in this situation?
Right now, he wants to forget about asset allocation, pie charts and “pie in
What if this were you in this situation?
Right now, he wants to forget about asset allocation, pie charts and “pie in
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
he sky” stories of long-term returns and growth rates. He told me that pretty soon, he won’t be worrying about “pie in the sky,” he’ll be wondering...
how to get pie on the table!
Moral of the
Moral of the
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
story: when the point and figure charts go on defense, we should heed the warning!
Please don’t get “sucked in” to the concept that the market returns an “average of ___% per year” and “over th
Please don’t get “sucked in” to the concept that the market returns an “average of ___% per year” and “over th
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
long haul” things will work out OK.
Just know that going on defense doesn’t mean the market will go immediately straight down.
What we DO know is that the risk of losing money in our accounts
Just know that going on defense doesn’t mean the market will go immediately straight down.
What we DO know is that the risk of losing money in our accounts
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
is much higher when the indicators are flashing defense. This has been the case since the bullish percent charts were created over 50 years ago.
If you want me to show you how these charts can
If you want me to show you how these charts can
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
uide you, just call me and I will GLADLY show you in less than 10 minutes.
This is where stock selection is key.
There has never been a more crucial time for you to be working with someone who
This is where stock selection is key.
There has never been a more crucial time for you to be working with someone who
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
watches the market on a daily basis. If you have any questions whatsoever regarding our game plan, you need to call me immediately at the office. The number is 732-223-9000.
Since the summer o
Since the summer o
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
1998, there have been four times where the S&P 500 has returned 20% or more. And there have been four times where the S&P 500 has LOST 20% or more. In just seven years!
But if you just sat th
But if you just sat th
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
ere and “held on,” no real progress was made. You can look it up; you’re right where you stood in 1998. Pretty soon it will be a decade where the “buy and hold” investor will have made no money
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.suggest.org.ua/article/104212/suggest-The-Point-Behind-Point--Figure.html">The Point Behind Point & Figure</a>
BB link (for phorums):
[url=http://www.suggest.org.ua/article/104212/suggest-The-Point-Behind-Point--Figure.html]The Point Behind Point & Figure[/url]
Related Articles:
Repeat Customers: Six Ways to Get and Keep Customers
How to Use a Landing Page Part II
Bookmark it:
|